These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [The place of drugs in health economics]. Sigvard J Therapie; 1977; 32(5):529-52. PubMed ID: 349766 [No Abstract] [Full Text] [Related]
4. [Responsibility for drug testing and control]. Büchi J Pharm Acta Helv; 1968 Sep; 43(9):619-27. PubMed ID: 5718866 [No Abstract] [Full Text] [Related]
5. [The Brazilian pharmaceutical market and the North American war effort]. Quintaneiro T Estud Hist; 2002; (29):141-64. PubMed ID: 18030707 [No Abstract] [Full Text] [Related]
6. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970. Tobbell DA Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387 [TBL] [Abstract][Full Text] [Related]
7. Responsibility for pharmaceutical company samples. Reti S N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193 [No Abstract] [Full Text] [Related]
8. [An analysis of the pharmaceuticals market in Vietnam]. Simonet D Sante; 2001; 11(3):155-60. PubMed ID: 11641078 [TBL] [Abstract][Full Text] [Related]
9. [Procedures and apparates for selection of intermediates and recommendation of used methods]. Germano A; Calvo B; Castagnola V; Maggi V Boll Chim Farm; 1970 Oct; 109(10):568-88. PubMed ID: 5515713 [No Abstract] [Full Text] [Related]
10. [Which factors should influence the choice of drugs?]. Lakartidningen; 1975 Oct; 72(40):3828-34. PubMed ID: 1177612 [No Abstract] [Full Text] [Related]
11. [Suggestions and recommendations for standardization of the systemic "routine" controls during the production of pharmaceutical forms and their manufacturing]. Bellentani L; Carugati E; Colombo A; Ingraffia P Boll Chim Farm; 1971 Jun; 110(6):298-311 contd. PubMed ID: 5110577 [No Abstract] [Full Text] [Related]
12. How much wine is enough for New Zealand? O'Hagan JJ N Z Med J; 1983 Apr; 96(730):295-8. PubMed ID: 6573587 [No Abstract] [Full Text] [Related]
13. Back to the future: driving innovation in drug development. Wagner JA Clin Pharmacol Ther; 2008 Feb; 83(2):199-202. PubMed ID: 18202681 [No Abstract] [Full Text] [Related]
14. [Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry]. Hansen L; Andersen D Ugeskr Laeger; 2005 May; 167(20):2160-4. PubMed ID: 15987073 [No Abstract] [Full Text] [Related]
15. PHARMAC: at what cost? Douglas B N Z Med J; 1999 Nov; 112(1099):433-4. PubMed ID: 10678229 [No Abstract] [Full Text] [Related]
16. Pharmaceutical products and government policies. Fernandez ST Indian J Ophthalmol; 1988; 36(1):1-2. PubMed ID: 3253190 [No Abstract] [Full Text] [Related]
17. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada. Openshaw MS Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902 [TBL] [Abstract][Full Text] [Related]
18. In business to treat cancer. Henig RM N Y Times Mag; 1986 Nov; ():68, 70, 78, 80+. PubMed ID: 11647805 [No Abstract] [Full Text] [Related]
19. Medical innovations and ethics: a state government perspective. Swidler RN Albany Law Rev; 1994; 57(3):655-77. PubMed ID: 11652859 [No Abstract] [Full Text] [Related]